A concentrated professional topical cosmetic matrix containing 60 billion NTA-documented extracellular vesicles in a compact 1 mL vial.

Designed for licensed aesthetic professionals seeking a high-count, low-volume formulation for precise topical application.

Product Overview

BioLife Concentrated Exosome Matrix 60B delivers a high extracellular-vesicle count in a convenient 1 mL professional-use format.

The extracellular vesicles are derived from three-dimensional bioreactor-cultured Wharton’s Jelly hUCT-MSC source cells.

Its concentrated format is designed for professionals who prefer precise topical application with less total fluid volume.

This product is supplied as a liquid cryopreserved formulation and contains no live or viable cells.

Product Specifications

• Extracellular-Vesicle Count: 60 billion per vial
• Fill Volume: 1 mL
• Source: Wharton’s Jelly hUCT-MSC source cells
• Culture Method: Three-dimensional bioreactor culture
• Format: Liquid cryopreserved topical matrix
• Formulation: Cell-free
• Intended Use: Professional topical cosmetic use

Product Highlights

• 60 billion extracellular vesicles per vial
• Compact and concentrated 1 mL format
• Particle count documented through Nanoparticle Tracking Analysis
• Wharton’s Jelly hUCT-MSC source
• Three-dimensional bioreactor-cultured source cells
• Liquid cryopreserved formulation
• Designed for precise topical application
• Cell-free cosmetic matrix
• Xeno-free and serum-free processing
• Endotoxin evaluation
• Sterility and mycoplasma testing
• Lot-specific Certificate of Analysis

Concentrated Professional Format

The BioLife Concentrated Exosome Matrix 60B is intended for qualified professionals seeking a high-count topical matrix in a compact volume.

Compared with the BioLife Topical Exosome Serum 12B, the 60B matrix provides five times the extracellular-vesicle count in one-tenth of the total application volume.

This concentrated format may be suitable for professional cosmetic services where precise, low-volume topical application is preferred.

Product selection and use must remain consistent with applicable regulations, professional scope-of-practice requirements, and BioLife Science product instructions.

Quality Documentation

Each released lot may be accompanied by a Certificate of Analysis documenting applicable quality and release specifications.

Lot-specific documentation may include:

• NTA-documented particle count
• Particle-size distribution
• Sterility results
• Mycoplasma results
• Endotoxin evaluation
• Lot identification
• Storage requirements
• Expiration or use-by information

Storage and Handling

Maintain frozen storage at the temperature specified in the accompanying product documentation.

The product should be transported using a validated frozen cold chain and transferred to the appropriate storage environment immediately after delivery.

Thaw only when ready for professional use. Do not refreeze after thawing. Follow the documented post-thaw period and all lot-specific handling instructions.

Important Notice

For professional topical cosmetic use only.

Not for injection, implantation, intravenous administration, or therapeutic use.

This product is not an FDA-approved drug or therapeutic agent and is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition.

BioLife Science does not provide dosing, administration, treatment, or clinical-use recommendations through this product listing.